Fast Track designation is designed to expedite clinical development and regulatory review timelines
Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including systemic lupus erythematosus; expect to report initial clinical data in 2025
Read more at globenewswire.com
